期刊文献+

替米沙坦辅助治疗高血压合并冠心病的疗效及对血压、血脂、左心室功能的影响 被引量:2

Effect of telmisartan on hypertension and coronary heart disease and its effect on blood pressure,blood lipid and left ventricular function
下载PDF
导出
摘要 目的对比分析替米沙坦辅助治疗高血压合并冠心病的疗效及对血压、血脂、左心室功能的影响。方法选取2017年8月至2020年6月该院收治的高血压合并冠心病患者170例,随机分为研究组和对照组,每组85例。对照组加用硝苯地平缓释片,研究组加用替米沙坦,连续治疗半年。对比观察两组患者治疗前后血压、血脂和左心室功能改变,统计其疗效。结果两组患者治疗后血脂水平较治疗前均无明显改变,血压较治疗前均明显下降,但两组患者治疗后血压比较,差异无统计学意义(P>0.05);左心室功能各项指标均有所变化,研究组患者室间隔厚度、左室后壁厚度、左心室舒张末内径、LVM、左心室质量指数均较治疗前及对照组治疗后更低,射血分数及E峰与A峰比值较治疗前及对照组治疗后更高,总有效率明显高于对照组,差异均有统计学意义(P<0.05)。结论采用替米沙坦治疗高血压合并冠心病患者不仅可有效控制血压,还可有效逆转左心室重构,改善患者心功能,提高临床疗效,值得临床推广应用。 Objective To comparatively analyze the effect of telmisartan on hypertension and coronary heart disease and its effect on blood pressure,blood lipid and left ventricular function.Methods A total of 170 hypertension patients with coronary heart disease who were admitted to our hospital from August 2017 to June 2020 were randomly divided into two groups.Patients in the control group were treated with nifedipine sustained release tablets.Patients in the observation group were treated with telmisartan.Six months.The changes of blood pressure,blood lipids,and left ventricular function before and after treatment were compared between the two groups of patients,and the efficacy was statistically analyzed.Results After treatment,blood lipid levels of the two groups had no significant changes compared with before treatment,and blood pressure decreased significantly before treatment,but there was no significant difference between the two groups(P<0.05),and all indexes of left ventricular function changed.Study group patients IVS,LVPW,LVDd,LVM,LVMI were significantly lower than before and after treatment in the control group.EF and E/A were significantly higher than before and after treatment in the control group,with significant difference(P<0.05).The clinical efficacy was significantly higher(97.6%vs.85.9%)than the control group(P<0.05).Conclusion Telmisartan is not only effective in controlling blood pressure in the treatment of hypertensive patients with coronary heart disease,but also can effectively reverse the left ventricular remodeling,improve the heart function of patients and improve the clinical treatment effect.It is worthy of clinical promotion and application.
作者 尹俊 庄红 黄璐 蒋伟 代天 张苏川 YIN Jun;ZHUANG Hong;HUANG Lu;JIANG Wei;DAI Tian;ZHANG Suchuan(The Sixth Hospital of Wuhan City,Affiliated Hospital of Jianghan University,Wuhan,Hubei 430000,China)
出处 《重庆医学》 CAS 2021年第S02期95-98,共4页 Chongqing medicine
关键词 替米沙坦 高血压 冠心病 血压 左心室功能 Telmisartan Hypertension Coronary heart disease Blood pressure left ventricular function
  • 相关文献

二级参考文献53

  • 1Czemichow S, Zanchetti A, Turnbull F , et at. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major car?diovascular events according to baseline blood pressure: meta-analysis of randomized trials(J). J Hypertens ,2011 ;29(1) :4-16.
  • 2Conroy RM, Pyooraalaa K, Fitzgerald AP , et at. Estimation of ten -year risk of fatal cardiovascular disease in Europe: the SCORE project[J] . Eur Heart J ,2003 ;24(11) :987-1003.
  • 3De Backer G, Petrella JR, Goudev AR, et at. Design and methodology of POWER, an open-label observation of the effect of primary care interven- tions on total cardiovascular risk in patients with hypertension[J]. Fun?dam Clin Phannacol,2013;27(2) :210-5.
  • 4Turnbull F. Blood pressure lowering treatment trialists' collaboration. Effects of differentblo,?d-pressure-Iowering regimens on major cardiovas?cular events: results of prospectively designed overviews of randomised trialsj J]. Lancet ,2003 ;362(9395) : 1527 -35.
  • 5Ambrosioni E, Bombelli M, Cerasola G, et al. Ambulatory monitoring of systolic hypertension in the elderly: eprosartanlhydrochlorothiazide com?pared with losartanlhydrochlorothiazide(INSIST trial)[J] . Adv Ther, 2010 ;27(6) :365-80.
  • 6Guallar E, Banegas JR, Blasco-Colmenares E, et at. Excess risk attributa?ble to traditional cardiovascular risk factors in clinical practice settings across Europe The EURIKA Study[J] . BMC Public Health, 2011 ; 11 : 704.
  • 7Xu FY , Yang B, Shi D, et al. Antihypertensive effects and safety of epro?sartan: a meta-analysis of randomized controlled trials[J] . Eur J Clin Phannacol,2012;68(2) :195-205.
  • 8Baumhalikel M, Boohm M. Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials[J] . Vase Health Risk Manag,2011 ;7 :391-7.
  • 9Flack JM, Nasser SA. Benefits of once-daily therapies in the treatment of hypertension[1). Vase Health Risk Manag, 20 II ; 7 : 777 -87.
  • 10De Backer G. The score model in the power study: an attempt to focus the limited resources for prevention on patients with greatest need[J]. CUIT Med Res Opin,2007 ;23(5) :SI9-24.

共引文献85

同被引文献25

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部